Loading…
Keros Therapeutics, Inc. is projected to rise to $13.60 by 2027, a +15% move from its current price of $11.80. KROS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $11.51 | $11.80 | $12.10 | +0.03% |
| Jul 13 | $11.40 | $11.81 | $12.23 | +0.07% |
| Jul 14 | $11.31 | $11.81 | $12.33 | +0.10% |
| Jul 15 | $11.24 | $11.82 | $12.42 | +0.14% |
| Jul 16 | $11.18 | $11.82 | $12.50 | +0.17% |
| Jul 17 | $11.13 | $11.82 | $12.57 | +0.20% |
| Jul 18 | $11.08 | $11.83 | $12.63 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.08 | $11.83 | $12.63 | +0.24% |
| Week 2 | $10.80 | $11.86 | $13.01 | +0.48% |
| Week 3 | $10.61 | $11.88 | $13.32 | +0.72% |
| Week 4 | $10.45 | $11.91 | $13.59 | +0.96% |
| Week 5 | $10.31 | $11.94 | $13.83 | +1.20% |
| Week 6 | $10.19 | $11.97 | $14.06 | +1.44% |
| Week 7 | $10.08 | $12.00 | $14.28 | +1.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics, Inc. (KROS) operates in the healthcare sector as a clinical-stage biopharmaceutical company. Its current price is $11.26 per share with a market capitalization of $222.86M.
The company is positioned at rank 3658 by market cap. The stock is analyzed with a bullish technical stance and a 30-day trading window that shows a range from $9.57 to $13.25. The stock is supported at $9.93 and faced with resistance at $11.39.
A major floor 22.4% below — a decisive break under it would weaken the trend.
The nearest floor, 15.8% below — buyers have tended to step in here.
Price is pressing into resistance (1.9% away) — a breakout level to watch.
A major ceiling 16.7% above — clearing it would confirm fresh momentum.
Key KROS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KROS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.64 | Buy | $11.66 | Buy |
| MA 10 | $11.29 | Buy | $11.39 | Buy |
| MA 20 | $10.89 | Buy | $11.12 | Buy |
| MA 50 | $10.99 | Buy | $11.20 | Buy |
| MA 100 | $11.65 | Buy | $12.13 | Sell |
| MA 200 | $14.65 | Sell | $14.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.93 | Neutral |
| Stoch RSI (14) | 79.36 | Neutral |
| CCI (20) | 135.54 | Buy |
| Williams %R (14) | -14.20 | Info |
| MACD (12,26,9) | 0.16 | Buy |
| ROC (12) | 7.27 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 85.80 | Sell |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | 0.80 | Buy |
| Ultimate (7,14,28) | 70.41 | Sell |
| Momentum (10) | 1.39 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 12.04 | Sell |
| ADX (14) | 14.60 | Neutral |
| ATR (14) | 0.26 | Info |
The 30-day technical picture shows bullish sentiment with an RSI(14) at 60. The 50-day simple moving average is $10.96 and the 200-day simple moving average is $14.76, indicating a near-term position above the 50-day average but below the longer-term average. Support is identified at $9.93 and resistance at $11.39, framing a recent trading range between $9.57 and $13.25.
Traders can expect near-term volatility within that range as price attempts to consolidate.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.91 | $11.80 | $16.30 | 0% | Neutral | |
| $10.92 | $13.60 | $17.86 | +15% | Neutral | |
| $13.62 | $17.40 | $23.65 | +47% | Bullish | |
| $14.87 | $19.40 | $27.08 | +64% | Bullish | |
| $15.49 | $20.58 | $29.38 | +74% | Bullish | |
| $16.46 | $22.24 | $32.38 | +88% | Bullish | |
| $15.58 | $21.37 | $31.67 | +81% | Bullish | |
| $16.71 | $23.26 | $35.03 | +97% | Bullish | |
| $19.11 | $26.97 | $41.22 | +129% | Bullish | |
| $20.75 | $29.66 | $45.97 | +151% | Bullish | |
| $24.76 | $37.56 | $61.66 | +218% | Bullish | |
| $50.37 | $84.52 | $150.99 | +616% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.91 | $11.80 | $14.39 | +0.00% |
| August 2026 | $10.40 | $12.24 | $14.79 | +3.77% |
| September 2026 | $10.27 | $12.17 | $14.85 | -0.59% |
| October 2026 | $10.58 | $12.61 | $15.51 | +3.59% |
| November 2026 | $10.98 | $13.14 | $16.28 | +4.21% |
| December 2026 | $10.87 | $13.07 | $16.30 | -0.55% |
Click any year to see its month-by-month KROS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KROS is projected to trade between $9.91 and $16.30, averaging $11.80 — a potential gain of 0% from today's $11.80. Price action looks broadly range-bound.
Keros Therapeutics, Inc.'s 2027 outlook centres on $13.60, within a $10.92 to $17.86 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, KROS could reach as high as $23.65, with a base case around $17.40 and support toward $13.62 — roughly +47% from $11.80. Momentum favours further upside here.
Expect KROS to range from $14.87 to $27.08 through 2029. The $19.40 average target implies a +64% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The KROS price prediction for 2030 points to an average of $20.58 (low $15.49, high $29.38) — a potential gain of +74% on today's $11.80. Momentum favours further upside here.
In 2031, KROS is projected to trade between $16.46 and $32.38, averaging $22.24 — a potential gain of +88% from today's $11.80. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Keros Therapeutics, Inc.'s 2032 outlook centres on $21.37, within a $15.58 to $31.67 range. That is -4% versus the projected 2031 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2033, KROS could reach as high as $35.03, with a base case around $23.26 and support toward $16.71 — roughly +97% from $11.80. Buyers look set to stay in control over this stretch.
Expect KROS to range from $19.11 to $41.22 through 2034. The $26.97 average target implies a +129% move from current prices. That is up +16% on the projected 2033 average. Momentum favours further upside here.
The KROS price prediction for 2035 points to an average of $29.66 (low $20.75, high $45.97) — a potential gain of +151% on today's $11.80. Buyers look set to stay in control over this stretch.
In 2040, KROS is projected to trade between $24.76 and $61.66, averaging $37.56 — a potential gain of +218% from today's $11.80. That is up +27% on the projected 2035 average. Momentum favours further upside here.
Keros Therapeutics, Inc.'s 2050 outlook centres on $84.52, within a $50.37 to $150.99 range. That is up +125% on the projected 2040 average. That marks a +616% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in KROS today (≈ 84.745763 KROS) could be worth
$7,162.86
+$6,162.86 (+616%) by 2050 · US Dollar
Based on the average projected KROS price of $84.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KROSwould be worth at today's price.
$1,000 invested in KROS on Jul 10, 2025 (≈ 69.108499 KROS) would be worth
$815.48
-$184.52 (-18.5%) today · 0.82× · US Dollar
Based on a KROS entry price of $14.47 vs. today's $11.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.26 | $1,047.96 | +4.8% |
| 1 month ago | $9.93 | $1,188.32 | +18.8% |
| 3 months ago | $11.2 | $1,053.1 | +5.3% |
| 6 months ago | $18.88 | $625 | -37.5% |
| 1 year ago | $14.47 | $815.48 | -18.5% |
| All time (5.0y) ago | $41.94 | $281.35 | -71.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KROS forecast.
Our base-case forecast reaches $24.00 around 2034.
Implied market cap at $24.00: $475M
The multi-year forecast depicts a rising average price across the listed years, starting from 2026 with an average of $11.26 and progressing to higher levels in subsequent years. By 2030, the average is projected at $18.03 with a 60.1% ROI, while 2040 shows an average of $29.82 with a ROI of 164.8%. In 2050, the average price is forecast at $64.77 with a dramatic ROI of 475.2%.
The sentiment remains BULLISH across many later years, reflecting expected long-run upside, though these figures are estimates and not guarantees. As always, outcomes depend on clinical progress, market conditions, and other unpredictable factors.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $18.03, with a min of $13.58 and a max of $25.73, and a ROI of 60.1%. The sentiment for 2030 is BULLISH.
The long-range forecast shows bullish sentiment in multiple years, with the average price rising to $64.77 by 2050 and a ROI of 475.2%. However, these figures are estimates and not guarantees, and risk factors exist.
The forecast max prices rise to $48.90 by 2040 and $115.53 by 2050, indicating it could exceed $50 by 2050 (2040 max is $48.90, 2050 max is $115.53).
Current price is $11.26 and market cap is $222.86M.
The 30-day range is $9.57 to $13.25. RSI(14) is 60, with SMA50 at $10.96 and SMA200 at $14.76. Support is $9.93 and resistance is $11.39, with a bullish overall tone.
Keros Therapeutics, Inc. Community Discussion
0Share your Keros Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.